product name Cinepazide maleate
Description: Cinepazide maleate is a maleate salt form of cinepazide which is a vasodilator. Cinepazide (3 mg/kg -30 mg/kg, i.v.) produces a dose-related and transient increase in vertebral, carotid, renal and femoral arterial flow as well as cardiac output and a decrease in total peripheral resistance in anesthetized dogs. Cinepazide exerts positive inotropic and chronotropic actions.
References: Nihon Yakurigaku Zasshi. 1979 Jul;75(5):507-16; Jpn J Pharmacol. 1986 May;41(1):109-15.
533.57
Formula
C22H31N3O5.C4H4O4
CAS No.
26328-04-1
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 107 mg/mL (200.5 mM)
Water: 107 mg/mL (200.5 mM)
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19403731
| In Vitro |
In vitro activity: Cinepazide (3 mg/kg -30 mg/kg, i.v.) produces a dose-related and transient increase in vertebral, carotid, renal and femoral arterial flow as well as cardiac output and a decrease in total peripheral resistance in anesthetized dogs. Cinepazide exerts positive inotropic and chronotropic actions. Cinepazide (30 mg/kg, i.v.) potentiates the vertebral vasodilator response of dogs to intravertebral adenosine and cyclic AMP. Intravertebral cinepazide (1 mg -10 mg) increases vertebral blood flow in a dose-related manner and the effect is partially inhibited by intravenous pretreatment with aminophylline but not by pretreatment with autonomic antagonists. Cinepazide is well absorbed and more than 60% of the dose is excreted within 24 hours. In 5 days, rats, dogs, and man excretes in the urine and faeces respectively 36.7% and 58.3%, 33.4% and 68.6%, and 61.3% and 38.1% dose. Cinepazide at doses of 1 mg/kg – 3 mg/kg i.v. decreases systemic blood pressure by 4% and reflexly increases heart rate by 8%. Cinepazide selectively stimulates the functional activities of 5-HT neurons in the brain, which are depressed by hypoxia. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Male Wistar rats |
| Animal model | Dissolved in saline; 4 mg/kg, 20 mg/kg, 100 mg/kg and 150 mg/kg; i.p. injection |
| Formulation & Dosage | |
| References | Nihon Yakurigaku Zasshi. 1979 Jul;75(5):507-16; Jpn J Pharmacol. 1986 May;41(1):109-15. |
Related Posts
product name Cinepazide maleate
Description: Cinepazide maleate is a maleate salt form of cinepazide which is a vasodilator. Cinepazide (3 mg/kg -30 mg/kg, i.v.) produces a dose-related and transient increase in vertebral, carotid, renal and femoral arterial flow as well as cardiac output and a decrease in total peripheral resistance in anesthetized dogs. Cinepazide exerts positive inotropic and chronotropic actions.
References: Nihon Yakurigaku Zasshi. 1979 Jul;75(5):507-16; Jpn J Pharmacol. 1986 May;41(1):109-15.
533.57
Formula
C22H31N3O5.C4H4O4
CAS No.
26328-04-1
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 107 mg/mL (200.5 mM)
Water: 107 mg/mL (200.5 mM)
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19403731
| In Vitro |
In vitro activity: Cinepazide (3 mg/kg -30 mg/kg, i.v.) produces a dose-related and transient increase in vertebral, carotid, renal and femoral arterial flow as well as cardiac output and a decrease in total peripheral resistance in anesthetized dogs. Cinepazide exerts positive inotropic and chronotropic actions. Cinepazide (30 mg/kg, i.v.) potentiates the vertebral vasodilator response of dogs to intravertebral adenosine and cyclic AMP. Intravertebral cinepazide (1 mg -10 mg) increases vertebral blood flow in a dose-related manner and the effect is partially inhibited by intravenous pretreatment with aminophylline but not by pretreatment with autonomic antagonists. Cinepazide is well absorbed and more than 60% of the dose is excreted within 24 hours. In 5 days, rats, dogs, and man excretes in the urine and faeces respectively 36.7% and 58.3%, 33.4% and 68.6%, and 61.3% and 38.1% dose. Cinepazide at doses of 1 mg/kg – 3 mg/kg i.v. decreases systemic blood pressure by 4% and reflexly increases heart rate by 8%. Cinepazide selectively stimulates the functional activities of 5-HT neurons in the brain, which are depressed by hypoxia. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Male Wistar rats |
| Animal model | Dissolved in saline; 4 mg/kg, 20 mg/kg, 100 mg/kg and 150 mg/kg; i.p. injection |
| Formulation & Dosage | |
| References | Nihon Yakurigaku Zasshi. 1979 Jul;75(5):507-16; Jpn J Pharmacol. 1986 May;41(1):109-15. |